Research Reports

Key takeaways

Brett Sandercock, CFO, Principal Financial Officer and Principal Accounting Officer, retires effective May 4, 2026, with no disagreements on company matters.

Sandercock transitions to Special Advisor through December 31, 2026, then consulting role through 2027, retaining salary, benefits, and equity vesting.

Aaron Bloomer, age 40, appointed CFO effective May 4, 2026, previously CFO at Exact Sciences Corporation.

Bloomer's compensation includes $725,000 base salary, $150,000 sign-on bonus (repayable if leaves within 24 months), 80% target short-term incentive, and $3,300,000 long-term equity grant.

Additional $3,300,000 equity grant eligible for FY2027, plus relocation assistance and standard executive severance arrangements.

Press release issued April 30, 2026, as Exhibit 99.1.

Full analysis

ResMed's announcement of CFO Brett Sandercock's retirement after 20 years in the role, transitioning smoothly to advisory positions through 2027, ensures continuity in financial leadership during the handover. The absence of any disagreements underscores an amicable departure, minimizing investor concerns over internal conflicts. Aaron Bloomer's appointment brings proven expertise from Exact Sciences, Baxter International, and 3M, with a track record in growth, margin expansion, and strategic M&A. His competitive compensation package, featuring a $725,000 base, significant sign-on and equity grants totaling potential $6.6 million over two years aligned with shareholder value via TSR metrics, and protective clawback provisions, positions him to drive ResMed's 2030 strategy. This leadership refresh signals proactive succession planning critical for a health technology firm focused on sustained growth.

RMD · ResMed Inc.

Summary

Key takeaways

Full analysis